Oestrogen receptor-alpha, breast cancer patients and tamoxifen response

Researchers have found evidence of a statistically significant survival benefit from adjuvant tamoxifen among patients whose oestrogen receptor (ER)-positive tumours had high levels of phosphorylation of ER-alpha; at serine-118 (ER-alpha S118-P), according to a brief communication published online November 25 in the Journal of the National Cancer Institute...

Read the whole article on

More from